A Novel Discriminant Score Based on Tumor-associated Trypsin Inhibitor for Accurate Diagnosis of Metastasis in Patients with Breast Cancer

Overview

Journal Tumour Biol

Publisher Sage Publications

Specialty Oncology

Date 2013 Nov 14

PMID 24222329

Citations 11

Authors

Hatem A El-Mezayen

Fatheya M Metwally

Hossam Darwish

Affiliations

Soon will be listed here.

Abstract

Invasion and metastasis of solid tumors require proteolytic enzymes for degradation of the basal membrane and extracellular matrix. Currently, there are no reliable methodologies to predict the risk for metastatic disease. In this context, our aim has been focused on the development of a noninvasive score based on tumor-associated trypsin inhibitor (TATI) for the assessment of metastasis in patients with breast cancer. TATI, trypsin, and soluble epidermal growth factor receptor (sEGFR) were assayed by enzyme-linked immunosorbent assay. CA 15.3 serum level was assayed by microparticle enzyme immunoassay in 265 patients with breast cancer. Statistical analyses were performed by logistic regression and receiver operating characteristic analysis curves. Using multivariate discriminant analysis, a score is selected based on absolute values of the four biochemical markers: TATI-metastatic breast cancer score (TATI-MBCS) = [0.03 × CA 15.3 (U/L) + 0.039 × TATI (ng/ml) + 0.04 × trypsin (ng/ml) + 0.023 × sEGFR (ng/ml) - 6.49 (numerical constant)]. This function correctly classified 84% of metastatic breast cancer at cutoff value = 0.62 (i.e., greater than 0.62 indicates patients with metastatic breast cancer and less than 0.62 indicates patients with nonmetastatic breast cancer). In conclusion, TATI-MBCS is a novel, noninvasive, and simple score which can be applied to discriminate patients with metastatic breast cancer.

Citing Articles

Raised SPINK1 levels play a role in angiogenesis and the transendothelial migration of ALL cells.

Luo D, Liu D, Rao C, Shi S, Zeng X, Liu S Sci Rep. 2022; 12(1):2999.

PMID: 35194087 PMC: 8864021. DOI: 10.1038/s41598-022-06946-6.

Functional Roles of SPINK1 in Cancers.

Lin T Int J Mol Sci. 2021; 22(8).

PMID: 33916984 PMC: 8067593. DOI: 10.3390/ijms22083814.

miR-5089-5p suppresses castration-resistant prostate cancer resistance to enzalutamide and metastasis via miR-5089-5p/SPINK1/ MAPK/MMP9 signaling.

Wang Z, Li Y, Wang K, Wang L, You B, Zhao D Aging (Albany NY). 2020; 12(14):14418-14433.

PMID: 32694237 PMC: 7425449. DOI: 10.18632/aging.103485.

Tazarotene-Induced Gene 1 (TIG1) Interacts with Serine Protease Inhibitor Kazal-Type 2 (SPINK2) to Inhibit Cellular Invasion of Testicular Carcinoma Cells.

Shyu R, Wang C, Wu C, Wang L, Chen M, Kuo C Biomed Res Int. 2019; 2019:6171065.

PMID: 31886233 PMC: 6899300. DOI: 10.1155/2019/6171065.

The Role of Serine Peptidase Inhibitor Kazal Type 13 (SPINK13) as a Clinicopathological and Prognostic Biomarker in Patients with Clear Cell Renal Cell Carcinoma.

Xu W, Shi S, Wang J, Xu Y, Tian X, Wan F Med Sci Monit. 2019; 25:9458-9470.

PMID: 31825950 PMC: 6926094. DOI: 10.12659/MSM.917754.

References

Kohn E, Liotta L . Molecular insights into cancer invasion: strategies for prevention and intervention. Cancer Res. 1995; 55(9):1856-62. View

Lukkonen A, Sorsa T, Salo T, Tervahartiala T, Koivunen E, Golub L . Down-regulation of trypsinogen-2 expression by chemically modified tetracyclines: association with reduced cancer cell migration. Int J Cancer. 2000; 86(4):577-81. DOI: 10.1002/(sici)1097-0215(20000515)86:4<577::aid-ijc21>3.0.co;2-j. View

Bast Jr R, Ravdin P, Hayes D, Bates S, Fritsche Jr H, Jessup J . 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2001; 19(6):1865-78. DOI: 10.1200/JCO.2001.19.6.1865. View

Stenman U . Tumour-associated trypsin inhibitor and tumour-associated trypsin. Scand J Clin Lab Invest Suppl. 1990; 201:93-101. View

Tomlins S, Rhodes D, Yu J, Varambally S, Mehra R, Perner S . The role of SPINK1 in ETS rearrangement-negative prostate cancers. Cancer Cell. 2008; 13(6):519-28. PMC: 2732022. DOI: 10.1016/j.ccr.2008.04.016. View

Moilanen M, Sorsa T, Stenman M, Nyberg P, Lindy O, Vesterinen J . Tumor-associated trypsinogen-2 (trypsinogen-2) activates procollagenases (MMP-1, -8, -13) and stromelysin-1 (MMP-3) and degrades type I collagen. Biochemistry. 2003; 42(18):5414-20. DOI: 10.1021/bi020582s. View

Egeblad M, Werb Z . New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2002; 2(3):161-74. DOI: 10.1038/nrc745. View

Sorsa T, Salo T, Koivunen E, Tyynela J, Konttinen Y, Bergmann U . Activation of type IV procollagenases by human tumor-associated trypsin-2. J Biol Chem. 1997; 272(34):21067-74. DOI: 10.1074/jbc.272.34.21067. View

Fox S, Smith K, Hollyer J, Greenall M, Hastrich D, Harris A . The epidermal growth factor receptor as a prognostic marker: results of 370 patients and review of 3009 patients. Breast Cancer Res Treat. 1994; 29(1):41-9. DOI: 10.1007/BF00666180. View

10.

Scheving L . Primary amino acid sequence similarity between human epidermal growth factor-urogastrone, human pancreatic secretory trypsin inhibitor, and members of porcine secretin family. Arch Biochem Biophys. 1983; 226(2):411-3. DOI: 10.1016/0003-9861(83)90309-0. View

11.

Paju A, Sorsa T, Tervahartiala T, Koivunen E, Haglund C, Leminen A . The levels of trypsinogen isoenzymes in ovarian tumour cyst fluids are associated with promatrix metalloproteinase-9 but not promatrix metalloproteinase-2 activation. Br J Cancer. 2001; 84(10):1363-71. PMC: 2363633. DOI: 10.1054/bjoc.2001.1806. View

12.

Hotakainen K, Bjartell A, Sankila A, Jarvinen R, Paju A, Rintala E . Differential expression of trypsinogen and tumor-associated trypsin inhibitor (TATI) in bladder cancer. Int J Oncol. 2005; 28(1):95-101. DOI: 10.3892/ijo.28.1.95. View

13.

Sandri M, Johansson H, Zorzino L, Salvatici M, Passerini R, Maisonneuve P . Serum EGFR and serum HER-2/neu are useful predictive and prognostic markers in metastatic breast cancer patients treated with metronomic chemotherapy. Cancer. 2007; 110(3):509-17. DOI: 10.1002/cncr.22825. View

14.

El-Mezayen H, Toson E, Darwish H, El-Badry E . Discriminant function based on parameters of hyaluronic acid metabolism and nitric oxide to differentiate metastatic from non-metastatic colorectal cancer patients. Tumour Biol. 2012; 33(4):995-1004. DOI: 10.1007/s13277-012-0332-4. View

15.

Wiksten J, Lundin J, Nordling S, Kokkola A, Stenman U, Haglund C . High tissue expression of tumour-associated trypsin inhibitor (TATI) associates with a more favourable prognosis in gastric cancer. Histopathology. 2005; 46(4):380-8. DOI: 10.1111/j.1365-2559.2005.02073.x. View

16.

Catarino M, Conde R . Tumor-associated trypsin inhibitor (TATI) in patients with colorectal carcinoma. A critical comparison with CEA. Scand J Clin Lab Invest Suppl. 1991; 207:43-6. DOI: 10.3109/00365519109104625. View

17.

Paju A, Vartiainen J, Haglund C, Itkonen O, Von Boguslawski K, Leminen A . Expression of trypsinogen-1, trypsinogen-2, and tumor-associated trypsin inhibitor in ovarian cancer: prognostic study on tissue and serum. Clin Cancer Res. 2004; 10(14):4761-8. DOI: 10.1158/1078-0432.CCR-0204-03. View

18.

Stenman U . Tumor-associated trypsin inhibitor. Clin Chem. 2002; 48(8):1206-9. View

19.

Gouyer V, Fontaine D, Dumont P, De Wever O, Fontayne-Devaud H, Leteurtre E . Autocrine induction of invasion and metastasis by tumor-associated trypsin inhibitor in human colon cancer cells. Oncogene. 2008; 27(29):4024-33. DOI: 10.1038/onc.2008.42. View

20.

Stenman U, Koivunen E, Itkonen O . Biology and function of tumor-associated trypsin inhibitor, TATI. Scand J Clin Lab Invest Suppl. 1991; 207:5-9. DOI: 10.3109/00365519109104618. View